Table 2.

Univariable and multivariable analyses of PFS and OS in the POEMS syndrome patients

Variables	PFS				OS
	Univariable Analyses		Multivariable Analyses		Univariable Analyses		Multivariable Analyses
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Male	2.275 (0.728–7.109)	0.158			1.948 (0.512–7.420)	0.328
Age ≥ 65 years	3.514 (1.267–9.743)	0.016	3.107 (1.108–8.715)	0.031	4.187 (1.258–13.937)	0.02	4.433 (1.265–15.531)	0.020
Organomegaly	1.787 (0.360–8.869)	0.477			2.371 (0.298–18.873)	0.415
Edocrinopathy	2.222 (0.286–17.277)	0.445			1.573 (0.198–12.493)	0.668
Skin changes	0.670 (0.226–1.982)	0.469			0.615 (0.174–2.172)	0.45
Extravascular volume overload	3.523 (0.772–16.070)	0.104	1.930 (0.413–9.027)	0.403	2.221 (0.474–10.411)	0.311
Bone lesions	0.726 (0.200–2.641)	0.627			0.441 (0.055–3.522)	0.44
VEGF elevation	0.358 (0.078–1.633)	0.185			1.163 (0.148–9.165)	0.886
TC < 3.00 mmol/L	4.393 (1.376–14.027)	0.012	4.124 (1.25–13.595)	0.020	7.200 (1.54–33.666)	0.012	7.887 (1.594–39.034)	0.011
HDL-C < 1.03 mmol/L	2.628 (0.515–13.41)	0.245			4.826 (0.586–39.732)	0.143	0.917 (0.056–15.024)	0.952
LDL-C < 2.60 mmol/L	2.601 (0.582–11.624)	0.211			1.594 (0.340–7.460)	0.554
TG > 2.25 mmol/L	0.607 (0.079–4.668)	0.632			0.914 (0.111–7.506)	0.933
Lp(a) > 300 mg/L	0.792 (0.273–2.294)	0.667			0.657 (0.190–2.269)	0.506

TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; Lp(a), lipoprotein (a); VEGF, vascular endothelial growth factor; PFS, progression-free survival; OS, overall survival